Valneva has launched an additional Phase 3 trial in Brazil of its VLA1553 live attenuated, single-dose chikungunya vaccine, the French company announced Monday.
The announcement follows previous Phase 3 data showing the Coalition for Epidemic Preparedness Innovations (CEPI)-backed shot produced neutralizing antibodies in 98.5% of participants and was well-tolerated in adults.
The new study tests the jab in adolescents ages 12 to…